Ackermann Mania, Dragon Anna Christina, Lachmann Nico
Institute of Experimental Hematology, RG Translational Hematology of Congenital Diseases, REBIRTH - Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany.
Institute for Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Transfus Med Hemother. 2020 Dec;47(6):444-453. doi: 10.1159/000512721. Epub 2020 Nov 16.
Antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages, are important regulators of the immune system, as they connect the innate and adaptive immunity by critically regulating T-cell responses. Thus, APCs are involved in both tissue homeostasis and tolerance, but also coordinate immune responses in case of infection and inflammation. Primary APCs are commonly generated from peripheral blood-derived monocytes and have been used as cell therapeutics in several (pre-)clinical settings, e.g., immune oncology, however, with varying efficiency. One promising alternative to study antigen presentation in vitro and to develop novel cell-based therapies are induced pluripotent stem cells (iPSCs). IPSCs can nowadays be generated from a variety of different cell types using several refined reprogramming techniques. Given their unlimited proliferation and differentiation potential, they hold great promise for regenerative medicine, and recently, first iPSC derivatives have found their way into first clinical studies for cell-based therapies. In this review article, we will give a brief overview of current methods for the generation and applications of primary APCs, but also specifically focus on different strategies for the generation of defined subsets of DCs and macrophages from human PSCs. Moreover, we will highlight the potential but also hurdles for the clinical translation of iPSC-derived APCs.
抗原呈递细胞(APCs),如树突状细胞(DCs)和巨噬细胞,是免疫系统的重要调节因子,因为它们通过严格调节T细胞反应来连接先天免疫和适应性免疫。因此,APCs既参与组织稳态和耐受性,也在感染和炎症情况下协调免疫反应。原代APCs通常由外周血来源的单核细胞产生,并已在多种(临床前)临床环境中用作细胞疗法,例如免疫肿瘤学,但其效率各不相同。诱导多能干细胞(iPSCs)是一种在体外研究抗原呈递和开发新型细胞疗法的有前途的替代方法。如今,可以使用几种精细的重编程技术从多种不同细胞类型中生成iPSCs。鉴于其无限的增殖和分化潜力,它们在再生医学中具有巨大的前景,最近,首批iPSC衍生物已进入基于细胞疗法的首批临床研究。在这篇综述文章中,我们将简要概述原代APCs的生成方法和应用,还将特别关注从人多能干细胞生成特定DCs和巨噬细胞亚群的不同策略。此外,我们将强调iPSC衍生的APCs临床转化的潜力和障碍。